Literature DB >> 24599919

Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity.

Francesco Ciccia1, Aroldo Rizzo1, Riccardo Alessandro1, Giuliana Guggino1, Rosario Maugeri1, Laura Saieva1, Alessandra Cannizzaro1, AnnaRita Giardina1, Giacomo De Leo1, Domenico Gerardo Iacopino1, Giovanni Triolo2.   

Abstract

OBJECTIVE: The aim of this study was to assess the expression of IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and p-STAT3 in muscle tissue from patients with PM and DM.
METHODS: Levels of IL-22, IL-22R1, IL-22BP and STAT3 mRNA were quantified by RT-PCR. The expression of IL-22, IL-22R1, IL-22BP and p-STAT3 was also analysed using immunohistochemistry.
RESULTS: Significant modulation of the IL-22 pathway was observed in inflammatory myopathic tissues. In particular, a significant overexpression of IL-22 at the protein but not the mRNA level was observed in PM/DM tissues and was correlated with myositis activity. IL-22R1 aberrant expression was also observed among infiltrating mononuclear cells and necrotic muscle cells. IL-22BP, which inhibits IL-22 signalling, was expressed only in some muscle fibres in PM/DM patients.
CONCLUSION: Our findings indicate that the IL-22 pathway is activated in inflammatory myopathic tissues and may be involved in the induction of muscle inflammatory processes and muscle necrosis.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  IL-17; IL-22; IL-22R1; dermatomyositis; p-STAT3; polymyositis

Mesh:

Substances:

Year:  2014        PMID: 24599919     DOI: 10.1093/rheumatology/keu005

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

Review 1.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis.

Authors:  Murat Giriş; Hacer Durmuş; Berrak Yetimler; Hatice Taşli; Yeşim Parman; Erdem Tüzün
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 3.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Association of interleukin 22 gene polymorphisms and serum IL-22 level with risk of systemic lupus erythematosus in a Chinese population.

Authors:  R Wang; Y-L Zeng; H-M Qin; Y-L Lu; H-T Huang; M Lei; T Tan; Y-Y Huang; H-C Luo; Y Lan; Y-S Wei
Journal:  Clin Exp Immunol       Date:  2018-05-23       Impact factor: 4.330

5.  Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.

Authors:  Tao Liu; Ying Hou; Ting-Jun Dai; Chuan-Zhu Yan
Journal:  Chin Med J (Engl)       Date:  2017-09-05       Impact factor: 2.628

6.  Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis.

Authors:  Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Kazuhisa Nakano; Shigeru Iwata; Ippei Miyagawa; Xiaoxue Ma; Gulzhan Trimova; Kei Sakata; Yoshiya Tanaka
Journal:  Front Immunol       Date:  2018-12-10       Impact factor: 7.561

Review 7.  STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.

Authors:  Stella Logotheti; Brigitte M Pützer
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

Review 8.  Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy.

Authors:  Xiuyun Xuan; Lin Zhang; Chunxia Tian; Ting Wu; Haihua Ye; Juanmei Cao; Fangqi Chen; Yan Liang; Huilan Yang; Changzheng Huang
Journal:  Cell Biosci       Date:  2021-01-06       Impact factor: 7.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.